Scientific Publications

NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro

NRX-101 (D-Cycloserine + Lurasidone), a Qualified Infectious Disease Product, is Active Against Drug-Resistant Urinary Pathogens In Vitro

NRX-101 (D-cycloserine plus lurasidone) vs. lurasidone for the maintenance of initial stabilization after ketamine in patients with severe bipolar depression with acute suicidal ideation and behavior: a randomized prospective phase 2 trial – Nierenberg International Journal of Bipolar Disorders

Community Ketamine Practices | American Journal of Psychiatry

D-Cycloserine For The Treatment Of Chronic Pain – Sapko, Javitt

Real Time Quality Assurance Of Depression Ratings In Psychiatric Clinical Trials – Korczykowski, MS, et. Al.

Peer-reviewed Biomarker Study, Dong, et. Al. – Frontiers of Psychiatry

NRX-101 Neurotoxicity Report on Ketamine in Rodent Model preprint

Abuse Liability Report on D-Cycloserine (DCS) preprint

PTSD Poster presented by Dr. Dan Javitt to the U.S. Army – Study of High Dose D-Cycloserine of Depression, Anxiety and PTSD

ACNP Poster Summarizing NRX-101 Clinical and Pre-Clinical Results

A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression- Heresco-Levy Paper

Pilot-controlled Trial of D-cycloserine for the Treatment of Post-Traumatic Stress Disorder – Herzog